drugset / Trial / NCT06846866

A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

NCT06846866

Phase 1 Completed 74 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics of BMS-986419 (Part 1) and the effects of multiple doses of BMS-986419 on cardiac repolarization (Part 2) in healthy participants.

Timeline

Start
2025-02-27
Primary completion
2025-10-21
Completion
2025-10-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986419 Unknown
Subject Moxifloxacin Small molecule

Indications

No indication recorded.